- Home
- SLRN
SLRN
ACELYRIN INC.
as 07-05-2024 2:37pm EST
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | AGOURA HILLS |
| Market Cap: | 436.7M | IPO Year: | 2023 |
| Target Price: | $12.80 | AVG Volume (30 days): | 825.0K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.67 - $29.88 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ACELYRIN INC. (SLRN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | SLRN | Chief Executive Officer | Apr 1 '24 | Sell | $6.63 | 9,961 | $66,024.50 | 1,577,374 | SEC Form 4 |
| Lin Shao-Lee | SLRN | Chief Executive Officer | Feb 20 '24 | Sell | $7.60 | 15,701 | $119,402.96 | 1,587,335 | SEC Form 4 |
| Lin Shao-Lee | SLRN | Chief Executive Officer | Jan 2 '24 | Sell | $7.41 | 10,691 | $79,188.24 | 1,603,036 | SEC Form 4 |
Latest ACELYRIN INC. News
SLRN Breaking Stock News: Dive into SLRN Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 hours ago
Here's Why We're Watching Acelyrin's (NASDAQ:SLRN) Cash Burn Situation
The Telegraph
a month ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
a month ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Simply Wall St.
a month ago
Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
Simply Wall St.
a month ago
Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
Motley Fool
a month ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
Simply Wall St.
a month ago
Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?
Simply Wall St.
a month ago
Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRN ACELYRIN INC. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.